Senseonics Stock Down Despite New FDA Approval for Eversense 365
BTIG Maintains Senseonics(SENS.US) With Hold Rating
Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older.
Express News | Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years Older
FDA Clearance Announcement Sends Small Cap Soaring
Senseonics Announces First CGM
